Influenza Infection Clinical Trial
Official title:
Effects of Gargling With Green Tea on Preventing Influenza Infection Among High School Students: A Randomized Clinical Study
Experimental and clinical studies in adults have reported that green tea catechins prevent influenza infection. In this clinical randomized study, the investigators aimed to determine the effects of gargling with green tea on the prophylaxis of influenza infection among high school teenagers.
Status | Recruiting |
Enrollment | 640 |
Est. completion date | August 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 15 Years to 20 Years |
Eligibility |
Inclusion Criteria: - aged from 15 to 20 years - obtained written informed consent from both the student and parent before participation - possible to gargle during 90 days - possible to fill in questionnaire Exclusion Criteria: - Possessing allergy to green tea - Possessing history of influenza infection within 6 months before entering the study - Possessing severe immune disease or whole body infection - severe cardiac, respiratory, renal, or hepatic dysfunction - diagnosed as inadequate to participate in the study by student doctor |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Japan | University of Shizuoka | Shizuoka |
Lead Sponsor | Collaborator |
---|---|
University of Shizuoka |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the incidence rates of influenza infection | Until 3 months gargling | No | |
Secondary | severity of influenza symptoms | until 3 months gargling | No | |
Secondary | influenza-free time during the study period | until 3 months gargling | No | |
Secondary | incidence of complications | until 3 months gargling | No | |
Secondary | incidence rates of upper respiratory tract infections | until 3 months gargling | No | |
Secondary | incidence of days of absence from school | until 3 months gargling | No | |
Secondary | occurrence of the adverse events | until 3 months gargling | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00603811 -
Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT03784885 -
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
|
Phase 2 | |
Recruiting |
NCT05436444 -
Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model
|
Phase 1 | |
Completed |
NCT01201902 -
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
|
Phase 3 | |
Completed |
NCT00559975 -
Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine
|
Phase 1 | |
Terminated |
NCT00647465 -
Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer
|
Phase 3 | |
Completed |
NCT01008020 -
Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection
|
N/A | |
Completed |
NCT00239213 -
Catechin Gargling for Influenza Infection
|
N/A | |
Terminated |
NCT04933968 -
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04298060 -
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
|
Phase 2 | |
Completed |
NCT01049490 -
Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device
|
N/A | |
Completed |
NCT02367885 -
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
|
Phase 1/Phase 2 | |
Completed |
NCT02313155 -
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT00812448 -
Catechin Containing Mask for the Prevention of Influenza Infection
|
N/A | |
Active, not recruiting |
NCT05818124 -
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
|
Phase 1 | |
Terminated |
NCT01160237 -
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
|
Phase 3 | |
Completed |
NCT03814720 -
Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
|
Phase 1 |